Curevo raises $110 million to advance amezosvatein

Seattle, USA-based biotech Curevo Vaccine, which is developing varicella zoster virus (VZV) vaccines with improved tolerability, today announces the closing of a $110 million Series B round to advance development of amezosvatein, its vaccine for shingles.

The global shingles vaccine market size was valued at $4.25 billion in 2023 and is projected to grow at a CAGR of 15.3% from 2024 to 2030 to some $17.83 billion. Recombinant vaccines such as UK pharma major GSK’s (LSE: GSK) Shingrix (zoster vaccine recombinant, adjuvanted) have gained significant market share due to their high efficacy. Full-year 2024 sales of Shingrix totaled £3.36 billion($4.36 billion).

Leading the round is new investor Medicxi, a European biotech-focused investment firm with significant experience investing in vaccine companies such as Vaxcyte and ViceBio. Joining Medicxi is an international group of investment funds including OrbiMed, HBM Healthcare Investments, and Sanofi Ventures plus existing investors RA Capital Management, Janus Henderson Investors, Adjuvant Capital, and founding investor GC Biopharma.